QD-based imaging probes can target pancreatic cancer at a very early stage[74,75] with the help of proteins/peptides directed against overexpressed surface receptors on cancer cells/tissues, such as the transferring receptor, antigen claudin-4, and urokinase plasminogen activator receptor[76-78]. Here, CLDN4 is linked to familial pancreatic carcinoma.